A. Arsene, I. Dumitrescu, C. Drăgoi, D. Udeanu, D. Lupuliasa, V. Jinga, D. Drăgănescu, C. Dinu‐Pîrvu, George Traian Alexandru Burcea Dragomiroiu, I. Blejan, Raluca Elisabeta Moisi, A. Nicolae, H. Moldovan, D. Popa, B. Velescu, S. Ruță
2020.4.15FARMACIA
tlooto Summary
The present study is reviewing the background of human coronaviruses, the potential viral reservoirs, the main genomic and pathogenic aspects of SARS-CoV-2 and the actual data on the immunopathological mechanisms of COVID 19, looking towards therapeutic approaches for SARS -CoV2 infection.
Abstract
Three zoonotic coronaviruses emerged at the beginning of the XXI century: SARS-CoV (Severe Acute Respiratory Syndrome coronavirus), Middle-East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV2 (previously known as 2019-nCoV), the etiologic agent of COVID 19 (Coronavirus disease) pandemic. The outbreak of the COVID-19 started in Wuhan, Hubei province, China, in December 2019 and has spread extremely fast worldwide. The World Health Organization declared it a pandemic on 11 March 2020. The present study is reviewing the background of human coronaviruses, the potential viral reservoirs, the main genomic and pathogenic aspects of SARS-CoV-2 and the actual data on the immunopathological mechanisms of COVID 19, looking towards therapeutic approaches for SARS-CoV2 infection.
Citation format
ARSENE, A., et al. A NEW ERA FOR THE THERAPEUTIC MANAGEMENT OF THE ONGOING COVID-19 PANDEMIC. FARMACIA, 2020, 68: 185–196.